# TRIPLE-SWITCH (NCT06592924)

> Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06592924
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Canadian Cancer Trials Group
- Conditions: Prostate Cancer (Adenocarcinoma)
- Interventions: Abiraterone; Enzalutamide; Apalutamide; Darolutamide (BAY 1841788); Docetaxel; ADT
- Enrollment: 830
- Primary outcome: Overall Survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 27
- YouTube: 19
- Podcasts: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=triple-switch-nct06592924

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06592924", "email": "<work email>"}; the inbox owner confirms by the emailed link.